Funding Round Backs Microbial Culture Technology

BioSilta Ltd, a developer of advanced microbial growth systems has received funding to support commercial expansion through direct sales and marketing teams in Europe and the USA; also for the establishment of distribution networks in other regions to increase sales of the Company’s EnPresso^® product line.

The EUR 2.5 million from Omega Funds (London) and existing investor Inveni Capital (Helsinki) will also be used to accelerate the introduction of new products in BioSilta’s pipeline. The Company’s offerings are based on its proprietary EnBase^® technology which offers a novel approach to control the feeding, and thereby growth rate, of microbial cultures.

Commenting on the investment, Renée Aguiar-Lucander, Partner at Omega Fund Management, said: “The market opportunity for products that improve protein yields and functionality is significant, and we are excited about backing an experienced team in this area able to fully leverage this new technology.

BioSilta has made significant progress in the last 12 months and we look forward to supporting the management team through this next stage of the Company’s growth.”

Markku Fagerlund, Partner at Inveni Capital, continued: “We’re delighted to have Omega Funds join us in investing in BioSilta and thereby enabling the Company to bring its products to a much wider market.”

Bob Penney, CEO at BioSilta, said: “Our current products significantly increase productivity enabling scientists to spend less time optimising protein expression systems and more time focused on their true research or development objectives. The funds will be used to drive market expansion with our current products and accelerate the introduction of new products in our pipeline.

We would like to thank our investors for supporting the Company at this exciting stage of its development.”